Browse News
Filter News
Found 37 articles
-
The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.
-
Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
8/10/2022
Artios Pharma Limited announces it has initiated a Phase 2 study with ART4215, a small molecule inhibitor of polymerase theta in combination with talazoparib, an oral poly polymerase inhibitor in an expansion study for the treatment of BRCA deficient breast cancer.
-
Artios Appoints Samantha Truex to Board of Directors
6/23/2022
Artios Pharma Limited (Artios), a clinical-stage biotech company pioneering the development of novel small molecule therapeutics that target the DNA damage response (“DDR”) process in order to treat patients suffering from a broad range of cancers, announces the appointment of Samantha Truex, a seasoned biotechnology executive, to its Board of Directors, effective June 15th, 2022.
-
Egle Therapeutics Appoints Pierre Legault as Chairman and Board Member
5/5/2022
Egle Therapeutics SAS, an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault as Chairman and board member as of March 2022.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Artios Announces ATR Inhibitor, ART0380, Development On Track and Progressing Into Phase 1b Evaluation
4/5/2022
Artios Pharma Limited announces that the development of its ataxia telangiectasia and Rad3-related Inhibitor, ART0380, has progressed into a Phase 1b dose expansion study targeting ATM deficient tumors.
-
EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies
2/22/2022
Eyebiotech Limited, a privately held ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, announced the completion of a successful $65 million Series A funding round.
-
Artios Appoints Nora Brennan to Board of Directors and Audit Committee Chair
11/16/2021
Artios Pharma Limited announces the appointment of Nora Brennan, an experienced financial executive in the healthcare industry, to its Board of Directors.
-
It was a busy week for clinical trial news. Here’s a look.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Artios Doses First Patient in Phase 1/2a Study of Polθ Inhibitor ART4215
9/28/2021
Artios Pharma Limited, a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA Damage Response process in order to treat patients suffering from a broad range of cancers, announces it has dosed the first patient in its Phase 1/2a study with its polymerase theta inhibitor, ART4215.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
-
Money on the Move: July 21 – 27, 2021
7/28/2021
A quick overview of life science companies scooping up some summer spending money this week. -
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
-
Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
7/27/2021
Artios Pharma Limited, a leading DNA Damage Response company exploiting a broad DDR-based platform and small molecule drug discovery capabilities to develop a diverse pipeline of product candidates for the treatment of cancer, announced the completion of a US$153 million Series C financing to fund further development of its promising clinical-stage pipeline.
-
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications
6/17/2021
Artios Pharma Limited announced the publication of a peer reviewed article titled, “Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance” in Nature Communications.
-
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer
5/4/2021
CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced the appointment of Dr. Phil L’Huillier as Chief Executive Officer, effective May 17, 2021.
-
Artios Pharma Limited has entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DDR targets and enhancing Novartis’ radioligand therapies.
-
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
4/7/2021
Artios eligible to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones in addition to royalty payments.
-
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.